What was the announcement from Pathkey.AI (ASX:PKY) regarding Imunexus Therapeutics?

Pathkey.AI has executed a strategic services agreement with Imunexus Therapeutics to deploy its TrialKey AI platform. This contract represents a shift from product development to commercialisation, turning the company's proprietary technology into a revenue-generating asset.

What is the total contract value of the Pathkey.AI (ASX:PKY) and Imunexus deal?

The agreement has a total potential value of up to A$100,000 plus GST. While this is a relatively small initial sum, it serves as a critical commercial proof-of-concept for the TrialKey platform.

How is the payment structured for Pathkey.AI (ASX:PKY) under this new agreement?

Pathkey.AI will receive an initial A$25,000 plus GST immediately upon the execution of the agreement. The remaining $75,000 plus GST is structured in three equal tranches.

Why is this contract significant for the Pathkey.AI (ASX:PKY) investment thesis?

This deal provides the first tangible commercial validation of Pathkey’s AI technology in a real-world setting. By embedding TrialKey into a third-party’s clinical trial design and risk assessment workflows, Pathkey.AI demonstrates that its platform has market value.

Over which financial years will this contract impact Pathkey.AI (ASX:PKY) revenue?

The deal is expected to contribute to Pathkey’s revenue across both the FY26 and FY27 financial years. The agreement has an initial term of one year, starting April 1..

What specific functions does the TrialKey platform perform for biotech clients?

TrialKey is used to assess the probability of success and development risks for new drugs. It also helps biotech companies optimise early-phase clinical trial designs before they are executed and benchmarks pipeline assets against global datasets.

What are the key risks associated with the Pathkey.AI (ASX:PKY) contract?

A major risk is that 75% of the contract value is contingent on Imunexus completing future capital raisings and hitting milestones. If Imunexus fails to secure funding or meet technical targets, Pathkey.AI may not realise the full $100,000 value.

Health

Image for illustrative purposes only. Not a real photo.

Pathkey.AI secures commercial contract with Imunexus

Written by Mahathir BayenaPublished Apr 2, 2026, 12:41 AMLast Updated Jul 6, 2026, 10:30 AM

Pathkey.AI (ASX:PKY), an Australian artificial intelligence technology firm, announced the execution of a strategic services agreement with Imunexus Therapeutics.

The commercial contract, valued at up to $100,000 plus GST, marks a pivotal advancement in Pathkey’s commercialisation strategy by converting its proprietary TrialKey platform into a revenue-generating asset.

The engagement provides immediate financial validation for the company’s AI capabilities, with an initial $25,000 plus GST payable upon execution.

The remaining $75,000 is structured in three equal tranches, contingent upon Imunexus achieving specific milestones and future capital raisings.

The partnership serves as a critical real-world validation of the TrialKey platform, as Imunexus integrates the technology into its live clinical development and capital-raising workflows.

The platform is being utilised for high-value applications, including the assessment of development risks, the optimisation of early-phase clinical trial designs, and the benchmarking of pipeline assets against extensive global datasets.

While the agreement features an initial one-year term, it is designed to establish a foundation for expanded engagement and follow-on work.

By securing this contract, Pathkey positions itself for sustainable growth, with the deal expected to contribute to revenue throughout FY26 and FY27.

Pathkey.AI secures commercial contract with Imunexus

Perguntas frequentes

Ativos relacionados a notícia